FL-WAX
22.11.2021 14:51:07 CET | Business Wire | Press release
Metasaurs , one of the fastest-growing NFT communities in the world, and WAX ($3.5B market cap), the most utilized blockchain in the world for games, processing three-quarters of all game-related transactions daily, announced a ground-breaking partnership to bring new world-class P2E (play-to-earn) games to the WAX ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122006228/en/
The creators of Metasaurs and founders of WAX will be co-founding a new NFT gaming studio, MetaGames to develop new game projects including the official Metasaurs Game and the launch of the RAWR token to be released in Q1 2022.
Since its inception in 2017, WAX has been coined “The King of NFTs,” but it’s so much more. WAX’s vIRL® technology is leading the future of digital commerce and it is the #1 blockchain by transaction volume in the world. It currently has more than 8M monthly users and is growing 400k+ users per month.
The WAX gaming-optimized blockchain processes 15 million transactions per day and is the #2 layer-1 blockchain behind only Ethereum in daily and 30 day NFT sales volume. Alien Worlds, one of the most popular games in the world, is built on the WAX blockchain, and independently boasts a $2.3B market cap for its own in-game economy.
"The foundation of WAX was built on gaming,” said William E. Quigley, co-founder of WAX, “and the official Metasaurs Game is the perfect use case for a play-to-earn gaming franchise created on WAX, taking advantage of our high volume transaction capacity, unique fee structure of no minting and gifting transaction fees, and energy efficient and low carbon footprint.”
Metasaurs are Dinosaur-Bored Ape hybrids of the popular Bored Ape Yacht Club NFT. The extended storyline, based on Dr. DMT, creating the Metasaurs, unlocks endless creative potential with regard to future games, avatars, and other multi-media on the WAX platform and across the emerging metaverse.
"It is our mission to create fun games which will share their economies with the lifeblood of the community—the players—rather than siphoning all value only to the publishers,” said Merlin Kauffman, creator of Metasaurs. ”Blockchain technology is best suited for this use-case, and we are excited to partner with WAX to create differentiated gaming experiences for the mass market."
“Merlin is a grassroots thought-leader in the NFT space,” said Quigley. “His track record building one of the most passionate fastest-growing NFT communities combined with our deep knowledge of NFT gaming economies put us in a privileged position to co-create the official Metasaurs Game. Our gaming studio, MetaGames, has all the right ingredients to create a series of successful play-to-earn gaming franchises.”
Quigley continued, “As we spend an increasing amount of time virtually than ever before, NFTs pave a way for users to have a stake in these new applications and digital worlds. WAX is at the forefront of this gaming evolution in the way we live online, building tools in a way that benefits everyone involved.”
About Metasaurs
The genesis Metasaurs collection is 9,999 NFTs created by Dr. DMT in The Lab from 300+ hand-drawn traits, each Metasaur consists of between 4-7 combined traits, of various rarities. Dr. DMT is authentic BAYC Ape #4588, and he is constantly developing new formulas to expand the Metasaurs experiment. The possibilities are endless, like the infinite lifespans of these Metasaurs on the blockchain .
About WAX - The King of NFTs
The Worldwide Asset eXchange ™ (WAX), aka the King of NFTs, is the world’s #1 blockchain, as measured by number of users and transactions, according to Dappradar.com. WAX’s mission is to bring NFTs to the mass market in the safest, most secure, environmentally friendly, and easy-to-use marketplace in the world. WAX is also the leading entertainment NFT network — in 2018, WAX introduced vIRLs® , giving consumer product companies the ability to directly link NFTs to physical consumer products.
About MetaGames Studio
Creators of world-class games, we are building the future of play-to-earn gaming experiences on the WAX blockchain. Co-founded by William Quigley, Merlin Kauffman, and Ben Bindell in 202, with initial studio development of the official Metasaurs Game and RAWR token to be released in Q1 2022. MetaGames ’ mission is to build branded social gaming communities that share their economies with the players, rather than siphoning all of the value only to the game publishers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006228/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom